ストックスクリーナーアプリを入手
85.04
0.40%
-0.34
プレマーケット:
85.55
0.51
+0.60%
Astrazeneca PLC (AZN) 最新ニュース
AstraZeneca sets $4.5bn Virginia API plant construction in motion - Pharmaceutical Technology
Turbine and AstraZeneca partner for ADC discovery - Pharmaceutical Technology
AstraZeneca: $4.5bn investment in Virginia - MarketScreener
AstraZeneca Lifts US Plant Investment to $4.5 Billion to Boost Drug Manufacturing - MarketScreener
AstraZeneca to Invest $4.5 Billion in New US Manufacturing Facility - MarketScreener
AstraZeneca breaks ground on enormous $4.5bn Virginia manufacturing plant - BioProcess International
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity DrugsAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca boosts investment in Virginia plant (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility By Investing.com - Investing.com South Africa
AstraZeneca to invest $4.5B in Virginia facility - breakingthenews.net
AstraZeneca ups investment at new Virginia facility to USD4.5 billion - MarketScreener
AstraZeneca to Boost Spending on Virginia Plant by $500 Million to $4.5 Billion - MarketScreener
AstraZeneca (AZN) Invests $4.5B in New Virginia Facility to Boos - GuruFocus
AstraZeneca to increase investment & scope of Virginia manufacturing facility to $4.5 bln - MarketScreener
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - MarketScreener
3,600 Jobs: AstraZeneca Expands Virginia Investment to $4.5B, Adds ADC Cancer Manufacturing - Stock Titan
Turbine Launches Collaboration with Astrazeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
What machine learning models say about AstraZeneca PLC Depositary ReceiptWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
AstraZeneca (LSE:AZN) Developments Within FTSE 100 and FTSE 350 Healthcare - Kalkine Media
AstraZeneca (AZN) Unaffected by Potential Tariffs on Generic Dru - GuruFocus
Volume spikes in AstraZeneca PLC Depositary Receipt stock – what they meanWeekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com
Algen inks $555m AstraZeneca partnership for AI-powered drug discovery - BioXconomy
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - MarketScreener
Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary Receipt2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Will AstraZeneca PLC Depositary Receipt bounce back from current supportEarnings Risk Report & High Yield Stock Recommendations - newser.com
AstraZeneca PLC $AZN Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca PLC Depositary Receipt recovery potential after sell off2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
AstraZeneca PLC Depositary Receipt stock momentum explained2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Stock of the Week: Is AstraZeneca a Buy After Share Price Jump? - Morningstar Canada
Barclays Keeps AstraZeneca at Overweight, Expects 'Resilient' Q3 Results - MarketScreener
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
What AstraZeneca Can Teach Us About Scaling Innovation Through Ecosystem Collaboration - MarketScreener
AstraZeneca Shares Surge 14% as Investment Pause Spurs Fresh Valuation Debate - Yahoo
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock - sharewise.com
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension - Benzinga
Another Baxdrostat Success Takes Pressure Off AstraZeneca - insights.citeline.com
AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension - MarketScreener
AstraZeneca (LSE:AZN): Exploring Valuation as Shares Move Steadily Higher - Yahoo Finance
AstraZeneca PLC $AZN Stock Holdings Lowered by Meitav Investment House Ltd. - MarketBeat
AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
AstraZeneca Reports Positive Bax24 Trial Results for Hypertension - AskTraders.com
AstraZeneca Says Phase 3 Trial of Baxdrostat Meets Endpoint in Resistant Hypertension - MarketScreener
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
AstraZeneca reports Phase III trial success for baxdrostat in hypertension - Investing.com
AstraZeneca PLC Announces Baxdrostat Demonstrates A Statistically Significant and Highly clinically meaningful Reduction in 24-Hour Systolic Blood Pressure Compared with Placebo - MarketScreener
AstraZeneca drug baxdrostat cuts blood pressure in key late-stage trial - MarketScreener
AstraZeneca and Daiichi’s Datroway trumps chemo in first-line breast cancer - Clinical Trials Arena
D.B. Root & Company LLC Cuts Stake in AstraZeneca PLC $AZN - MarketBeat
BreakingviewsAstraZeneca’s New York shift augurs London exodus - Reuters
AstraZeneca blood pressure drug succeeds in late-stage trial - Financial Times
AstraZeneka presents results for patients with resistant hypertension - MarketScreener
AstraZeneca’s experimental hypertension drug shows promising results - Investing.com
AstraZeneca’s baxdrostat hits key goal in major blood pressure trial - Proactive financial news
AstraZeneca says baxdrostat met primary endpoint in BAX24 Ph3 trial - MarketScreener
AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial - MarketScreener
REGAstraZeneca PLCBaxdrostat met primary endpoint in Bax24 Ph3 trial - TradingView
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases - Benzinga
AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treat - GuruFocus
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study - Seeking Alpha
AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer - BioPharma Dive
AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC - insights.citeline.com
AstraZeneca signs up to $555 million AI deal with Algen to develop therapies - Reuters
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy - AOL.com
Can AstraZeneca keep on growing? - Investors' Chronicle
大文字化:
|
ボリューム (24 時間):